Vaxcyte (PCVX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vaxcyte (PCVX)
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Key Insights
Critical company metrics and information
Share Price
$93.04Market Cap
$11.60 BillionTotal Outstanding Shares
124.64 Million SharesTotal Employees
254Dividend
No dividendIPO Date
June 12, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.vaxcyte.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $505.27 Million |
| Exchange Gains/Losses | $-8.61 Million |
| Net Cash Flow From Operating Activities, Continuing | $-470.04 Million |
| Net Cash Flow From Financing Activities | $2.45 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-1.46 Billion |
| Net Cash Flow, Continuing | $513.88 Million |
| Net Cash Flow From Operating Activities | $-470.04 Million |
| Net Cash Flow From Financing Activities, Continuing | $2.45 Billion |
| Net Cash Flow From Investing Activities | $-1.46 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Revenues | $0.00 |
| Research and Development | $447.18 Million |
| Operating Income/Loss | $-604.05 Million |
| Basic Earnings Per Share | $4.60 |
| Depreciation and Amortization | $5.10 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-507.65 Million |
| Operating Expenses | $604.05 Million |
| Diluted Average Shares | $239.96 Million |
| Net Income/Loss | $-507.65 Million |
| Net Income/Loss Attributable To Parent | $-507.65 Million |
| Income/Loss From Continuing Operations Before Tax | $-507.65 Million |
| Diluted Earnings Per Share | $4.60 |
| Basic Average Shares | $239.96 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-507.65 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Other Operating Expenses | $151.77 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Fixed Assets | $163.24 Million |
| Non-current Prepaid Expenses | $284000.00 |
| Assets | $3.56 Billion |
| Prepaid Expenses | $10.59 Million |
| Other Current Assets | $2.20 Billion |
| Equity | $3.42 Billion |
| Liabilities | $142.11 Million |
| Liabilities And Equity | $3.56 Billion |
| Equity Attributable To Parent | $3.42 Billion |
| Noncurrent Assets | $1.35 Billion |
| Accounts Payable | $18.22 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Current Assets | $2.21 Billion |
| Other Current Liabilities | $93.33 Million |
| Other Non-current Assets | $1.18 Billion |
| Noncurrent Liabilities | $18.32 Million |
| Wages | $12.24 Million |
| Current Liabilities | $123.79 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.